Skip to content
Inciteful Med

Building Your Care Team and Long-Term Monitoring

Last updated:

Managing Alpha-1 Antitrypsin Deficiency requires a multidisciplinary care team, including a pulmonologist, hepatologist, and genetic counselor. Regular long-term monitoring of lung and liver health, along with family screening, is essential to catch changes early and protect your future.

Key Takeaways

  • • A specialized multidisciplinary care team for AATD should include a pulmonologist, hepatologist, genetic counselor, and primary care physician.
  • • Long-term lung monitoring involves annual breathing tests like spirometry and DLCO, along with sensitive low-dose CT scans.
  • • Liver health must be tracked regularly using liver enzyme blood tests and FibroScan elastography, even if no symptoms are present.
  • • All first-degree relatives (parents, siblings, and children) should be tested for AATD due to its genetic nature.
  • • Connecting with support groups and patient advocacy organizations can help manage the emotional impact and stress associated with chronic monitoring.

Managing Alpha-1 Antitrypsin Deficiency (AATD) is a lifelong commitment that is best handled by a specialized team [1][2]. Because AATD can affect multiple parts of the body and carries genetic implications for your family, your care should be “multidisciplinary”—meaning it involves several different types of experts working together [1][3].

Building Your Care Team

Ideally, your care should be coordinated through a specialized Alpha-1 “reference center” or a doctor who has deep experience with the condition [1][4]. Your team should include:

  • Pulmonologist: This specialist manages your lung health, monitors your breathing tests, and determines if you need augmentation therapy [5][6].
  • Hepatologist: Even if you don’t have liver symptoms, a liver specialist is crucial for monitoring potential protein clumping and scarring (fibrosis) [6][7].
  • Genetic Counselor: These professionals help you understand your lab results and guide you through the process of talking to your family members about their own risks [8][1].
  • Primary Care Physician (PCP): Your PCP remains the “hub” for your overall health, ensuring you stay up-to-date on vaccinations (like flu and pneumonia shots) that are vital for protecting your lungs [9].

Your Roadmap for Long-Term Monitoring

AATD is often a slow-moving condition, and regular check-ups allow your team to catch changes early [10][11].

Lung Monitoring

  • Spirometry and DLCO: These are breathing tests performed at least once a year to measure how much air you can hold and how well your lungs transfer oxygen to your blood [12][13].
  • CT Densitometry: Specialized “low-dose” CT scans are the most sensitive way to track the actual loss of lung tissue (emphysema) over time [14][10].

Liver Monitoring

  • Liver Enzymes: Regular blood tests check for signs of liver inflammation [15][16].
  • FibroScan (Elastography): This non-invasive ultrasound-like test measures the “stiffness” of your liver, which helps detect scarring (fibrosis) before it becomes severe [15][17].

Family Screening: The “Cascade” Effect

Because AATD is a genetic condition, your diagnosis is a vital piece of information for your relatives [9][8].

  • Who should be tested? Guidelines strongly recommend testing all “first-degree” relatives—this includes your parents, siblings, and children [9][18].
  • Why test? Early diagnosis in family members allows them to make healthy lifestyle choices (like never starting smoking) and begin monitoring before damage occurs [8][19].

The Psychological Impact and Finding Support

Living with a chronic condition that requires constant monitoring can be emotionally heavy [3]. It is common to experience:

  • “Scanxiety”: Stress or anxiety leading up to your annual breathing tests or scans [8].
  • Perceived Stigma: Feeling judged for respiratory symptoms, especially if you have a history of smoking [20].
  • Patient Advocacy Organizations: Dedicated organizations, such as the Alpha-1 Foundation, are incredible resources for finding local support groups, identifying specialized Alpha-1 reference centers, and staying informed about new research and clinical trials [1].
  • The Power of Support: Research shows that patients with strong social support—from family, friends, or Alpha-1 support groups—report higher life satisfaction and lower stress levels [20][21]. Don’t hesitate to seek out mental health support as a standard part of your care [3].

Frequently Asked Questions

Which doctors should be on my AATD care team?
Your core team should ideally include a pulmonologist for lung health, a hepatologist for liver monitoring, a genetic counselor, and a primary care physician to coordinate overall care and vaccinations.
How often do I need my lungs checked if I have Alpha-1?
You should have breathing tests, such as spirometry and DLCO, at least once a year. Your doctor may also recommend specialized low-dose CT scans to track any loss of lung tissue over time.
Do I need to see a liver doctor if I don't have liver symptoms?
Yes, consulting a hepatologist is crucial even without symptoms. They can perform regular blood tests and a non-invasive FibroScan to detect early signs of liver inflammation or scarring before it becomes severe.
Which family members should be tested for Alpha-1?
Guidelines strongly recommend testing all first-degree relatives. This includes your parents, siblings, and children, so they can make informed health choices and begin monitoring early if necessary.
Where can I find support for the emotional impacts of AATD?
Patient advocacy organizations like the Alpha-1 Foundation can connect you with local support groups and specialized reference centers. Seeking mental health support is a standard and highly recommended part of managing the stress of chronic monitoring.

Questions for Your Doctor

  • • How many other patients with Alpha-1 do you currently treat in your practice?
  • • Will you be coordinating my care with a hepatologist and a genetic counselor?
  • • Which specific lung function tests (like DLCO or spirometry) will we use to track my progression, and how often?
  • • When should we schedule my first 'baseline' FibroScan or liver ultrasound?
  • • Can you provide a letter or resources to help me explain the importance of genetic testing to my siblings and children?

Questions for You

  • • How do I feel about my current doctors? Do they seem familiar with the latest Alpha-1 treatment guidelines?
  • • Which of my first-degree relatives (parents, siblings, children) have I talked to about my diagnosis?
  • • Have I noticed changes in my mood, such as increased anxiety or sadness, since my diagnosis? (Chronic monitoring can be emotionally taxing).
  • • Is there a local or online Alpha-1 support group I can join to connect with others who understand this journey?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Alpha-1 Antitrypsin Deficiency: Principles of Care.

    Rodrigues JF, Mineiro A, Reis A, et al.

    Acta medica portuguesa 2020; (33(6)):433-439 doi:10.20344/amp.12950.

    PMID: 32504520
  2. 2

    Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.

    Henao MP, Craig TJ

    Expert review of respiratory medicine 2016; (10(12)):1281-1294 doi:10.1080/17476348.2016.1249851.

    PMID: 27771979
  3. 3

    Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life.

    Beiko T, Strange C

    Therapeutics and clinical risk management 2019; (15()):959-964 doi:10.2147/TCRM.S175369.

    PMID: 31534340
  4. 4

    The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency.

    Miravitlles M, Nuñez A, Torres-Durán M, et al.

    COPD 2020; (17(4)):346-354 doi:10.1080/15412555.2020.1795824.

    PMID: 32791925
  5. 5

    Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence.

    Brantly ML, Lascano JE, Shahmohammadi A

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (6(1)):100-114 doi:10.15326/jcopdf.6.1.2017.0185.

    PMID: 30775428
  6. 6

    Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.

    Abreu N, Pereira VM, Pestana M, Jasmins L

    GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.

    PMID: 37868641
  7. 7

    Surgery for patients with Alpha 1 Antitrypsin Deficiency: A review.

    Zamora M

    American journal of surgery 2019; (218(3)):639-647 doi:10.1016/j.amjsurg.2018.10.019.

    PMID: 30360894
  8. 8

    Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.

    Foil KE

    Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211015954 doi:10.1177/20406223211015954.

    PMID: 34408833
  9. 9

    The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

    Sandhaus RA, Turino G, Brantly ML, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.

    PMID: 28848891
  10. 10

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  11. 11

    The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.

    Campos MA, Diaz AA

    Chest 2018; (153(5)):1240-1248 doi:10.1016/j.chest.2017.11.017.

    PMID: 29175361
  12. 12

    Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry.

    Faria N, Gomes J, Guimarães C, et al.

    Respiration; international review of thoracic diseases 2024; (103(6)):317-325 doi:10.1159/000537759.

    PMID: 38531325
  13. 13

    Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.

    Esmaili S, Rodríguez Hermosa JL, Vargas Centanaro G, et al.

    Biomolecules 2025; (15(4)) doi:10.3390/biom15040599.

    PMID: 40305326
  14. 14

    Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.

    Sandhaus RA

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S370-3 doi:10.1513/AnnalsATS.201510-684KV.

    PMID: 27564674
  15. 15

    Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

    Loomba R, Clark VC, Mandorfer M, et al.

    Gastroenterology 2025; doi:10.1053/j.gastro.2025.12.012.

    PMID: 41390004
  16. 16

    Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study.

    Cakir M, Sag E, Islek A, et al.

    Pediatric gastroenterology, hepatology & nutrition 2020; (23(2)):146-153 doi:10.5223/pghn.2020.23.2.146.

    PMID: 32206627
  17. 17

    Association of circulating Z-polymer with adverse clinical outcomes and liver fibrosis in adults with alpha-1 antitrypsin deficiency.

    Fromme M, Rademacher L, Amzou S, et al.

    United European gastroenterology journal 2024; (12(8)):1091-1101 doi:10.1002/ueg2.12629.

    PMID: 39024029
  18. 18

    The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status.

    Tejwani V, Nowacki AS, Fye E, et al.

    Respiratory care 2019; (64(8)):915-922 doi:10.4187/respcare.06555.

    PMID: 30914495
  19. 19

    Detection of alpha-1 antitrypsin deficiency: the past, present and future.

    Brantly M, Campos M, Davis AM, et al.

    Orphanet journal of rare diseases 2020; (15(1)):96 doi:10.1186/s13023-020-01352-5.

    PMID: 32306990
  20. 20

    A Stress Buffering Perspective on the Progression of Alpha-1 Antitrypsin Deficiency.

    Tian X, Solomon DH, Smith RA

    Health communication 2020; (35(6)):747-755 doi:10.1080/10410236.2019.1584782.

    PMID: 30843437
  21. 21

    Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency.

    Rueda JD, Sieluk J, Sandhaus RA, Mullins CD

    Value in health regional issues 2020; (23()):70-76 doi:10.1016/j.vhri.2020.04.003.

    PMID: 32892111

This page is for informational purposes only and does not replace professional medical advice. Always consult your Alpha-1 specialist or healthcare provider about your specific care team and monitoring schedule.

Stay up to date

Get notified when new research about Alpha-1-antitrypsin deficiency is published.

No spam. Unsubscribe anytime.